Ruxolitinib for Myeloproliferative Neoplasms Worsens Cardiometabolic Health

Ruxolitinib, an oral JAK1/2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of myeloproliferative neoplasms (MPNs), is associated with worsening cardiometabolic health, according to an article published in Scientific Reports. The retrospective study analyzed data from 69 adults (mean age, 65 years) with MPNs who initiated ruxolitinib between 2010 and 2017 … Continue reading Ruxolitinib for Myeloproliferative Neoplasms Worsens Cardiometabolic Health